Drug trio for a fast-growing type of mantle cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial is testing a combination of three drugs (linperlisib, obinutuzumab, and venetoclax) for people with a fast-growing type of mantle cell lymphoma that has come back or not responded to other treatments. The goal is to see if this drug combo can help shrink the lymphoma and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You need a confirmed diagnosis of the blastoid variant of mantle cell lymphoma (a fast-growing type).
- You should be generally active and able to care for yourself (ECOG score 0-2).
- You must have at least one measurable sign of lymphoma, like an enlarged lymph node, an enlarged spleen, or lymphoma in the bone marrow.
- You cannot have taken PI3K inhibitors or BCL-2 inhibitors before.
- Your liver, kidneys, blood counts, and organ function need to be within a certain range (tests will be done).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (glofitamab, orelabrutinib, and bortezomib) to see if it is safe and effective for people with a fast-growing or hard-to-treat type of mantle cell lymphoma. If you have high-risk features, this therapy might be an option.
This trial tests a combination of three medications (zanubrutinib, obinutuzumab, and sonrotoclax) for people with mantle cell lymphoma, a type of blood cancer. The goal is to see if this combination is safe and effective, and it may be an option for people who are older or have health issues that make a stem cell transplant too risky.
This trial tests a combination of three drugs (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma. The goal is to see if this combination works better for high-risk or older patients.
This Phase 2 trial tests how well the combination of pirtobrutinib and venetoclax works for people with mantle cell lymphoma that has come back or did not respond to treatment. It’s meant to help shrink the lymphoma and improve outcomes after prior therapies.
This early-phase study tests a combination of venetoclax, lenalidomide, and rituximab in people newly diagnosed with mantle cell lymphoma. It aims to control the lymphoma and see how safe and effective this approach is for newly treated patients.
This trial tests a combination of three targeted drugs for mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see if this new drug cocktail can work better than standard options.
Hear when a new Mantle Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.